Informed consent to microsatellite instability and immunohistochemistry screening for Lynch syndrome

Genetics in Medicine

Volumn 13, Issue 4, 2011, Pages 356-360

  Chubak, Barbara ^a   Heald, Brandie ^b   Sharp, Richard R ^a,b,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

colorectal cancer; ethics; HNPCC; IHC screening; informed consent; Lynch syndrome; MSI screening

Indexed keywords

ARTICLE; GENETIC ANALYSIS; GENETIC SCREENING; GERMLINE MICRONUCLEUS; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; INFORMED CONSENT; MEDICAL ETHICS; MEDICAL PRACTICE; MICROSATELLITE INSTABILITY; PROTEOMICS; RISK ASSESSMENT;

COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; GENETIC TESTING; HUMANS; IMMUNOHISTOCHEMISTRY; INFORMED CONSENT; MICROSATELLITE INSTABILITY; PROTEOMICS;

EID: 79954993020     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e31820aee09     Document Type: Article

References (28)

1. American Cancer Society. Colorectal Cancer Facts and Figures 2008-2010. Available at: http://www.cancer.org/downloads/STT/F861708-finalforweb.pdf. Accessed April 27, 2010.
2. Burt R, Neklaston DW. Genetic testing for inherited colon cancer. Gastroenterology 2005;128:1696-1716. (Pubitemid 40692561)
3. Lynch HT, Smyrk TC, Watson P, et al. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology 1993;104:1535-1549. (Pubitemid 23235432)
4. Vasen HF, Moslein G, Alonzo A, et al. Guidelines for the clinical management of Lynch syndrome (HNPCC). J Med Genet 2007;44:353-362. (Pubitemid 46953715)
5. Hampel H. Genetic testing for hereditary colorectal cancer. Surg Oncol Clin N Am 2009;18:687-703.
6. Chapman PD, Burn J. Genetic predictive testing for bowel cancer predisposition: the impact on the individual. Cytogenet Cell Genet 1999;86:118-124. (Pubitemid 29488303)
7. Kaz AM, Brentnall TA. Genetic testing for colon cancer. Nat Clin Pract 2006;3:670-679. (Pubitemid 44824695)
8. Jarvinen HJ. Genetic testing for polyposis: practical and ethical aspects. Gut 2003;52(suppl 2):19-22.
9. EGAPP Working Group. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colo-rectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 2009;11:35-41.
10. Kievit W, de Bruin JH, Adang EM, et al. Current clinical selection strategies for identification of hereditary non-polyposis colorectal cancer families are inadequate: a meta-analysis. Clin Genet 2004;126:42-48.
11. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda guidelines for hereditary non-polyposis colorectal cancer (Lynch syndrome) and microsat-ellite instability. J Natl Cancer Inst 2004;96:261-268. (Pubitemid 38256271)
12. Mvundura M, Grosse SD, Hampel H, et al. The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med 2010;10:1-12.
13. De la Chapelle A. Microsatellite instability. N Engl J Med 2003;349:209-210.
14. Lynch HT, Lynch PM, Lanspa SJ, et al. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicole-gal ramifications. Clin Genet 2009;76:1-18.
15. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349:247-257. (Pubitemid 36859476)
16. Shia J, Zhang L. Point/counterpoint: immunohistochemistry versus micro-satellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colon cancer syndrome. J Mol Diagn 2008;10:293-307.
17. Hampel H, Frankel WL, Martin E, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 2008;26: 5783-5788.
18. Faden R, Beauchamp T. A history and theory of informed consent. Oxford: Oxford University Press, 1986.
19. Berg JW, Appelbaum PS, Parker LS, et al. Informed consent: legal theory and clinical practice, 2nd ed. Oxford: Oxford University Press, 2001.
20. Feld AD. Medicolegal implications of colon cancer screening. Gastrointest Endosc Clin N Am 2002;12:171-179. (Pubitemid 34072788)
21. Juengst ET. FACE facts: why human genetics will always provoke bioethics. J Law Med Ethics 2004;32:267-275. (Pubitemid 38903357)
22. Rothstein M, Anderlik MA. What is genetic discrimination and when and how can it be prevented? Genet Med 2001;3:354-358.
23. Sorenson JR. Genetic counseling: values that have mattered. In: Bartels D, LeRoy B, Caplan A, editors. Prescribing our future: ethical challenges in genetic counseling. New York: Aldine de Gruyter, 1993:3-14.
24. American Society for Clinical Oncology (ASCO). ASCO policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 2003;21:2397-2406.
25. Genetic Information Nondiscrimination Act (GINA). Pub. L. No. 110-233, 122 Stat. 881, 2008.
26. Sharp RR. Is informed consent necessary for MSI/IHC screening for HN-PCC? Paper presented at American College of Medical Genetics. Albuquerque, NM, March 24, 2010.
27. Rubin DT, Gandhi RK, Hetzel JT, et al. Do colorectal cancer patients understand that their family is at risk? Dig Dis Sci 2009;54:2473-2483.
28. Fuchs CS, Giovannucci EL, Colditz GA, et al. A prospective study of family history and the risk of colorectal cancer. N Engl J Med 1994;331:1669-1674. (Pubitemid 24373618)